Dagan et al. [47] assessed the relevance of AR CAG repeat length and ovarian cancer risk in Jewish Israeli women who are BRCA1/2 mutation carriers, and null results were concluded, most likely due to the small sample size. The gene discussed is AR; the disease is ovarian carcinoma.